[{"orgOrder":0,"company":"Criceto Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Criceto Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Criceto Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Criceto Pharmaceuticals \/ Orion Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Criceto Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Under the licensing agreement, Orion will hold the exclusive rights of the Aporon(apomorphine HCl), which is being evaluated for the treatment of OFF episodes in patients with Parkinson’s disease.

                          Product Name : Aporon

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 25, 2025

                          Lead Product(s) : Apomorphine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Orion Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank